Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Filana Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Filana Therapeutics, Inc.’s stock price such as:

• Filana Therapeutics, Inc.’s current stock price and volume
• Why Filana Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for FLNA from analysts
• FLNA’s stock price momentum as measured by its relative strength

About Filana Therapeutics, Inc. (FLNA)

Before we jump into Filana Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer’s disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.

Want to learn more about Filana Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Filana Therapeutics, Inc..

Filana Therapeutics, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Filana Therapeutics, Inc.’s stock price was $1.010.

Filana Therapeutics, Inc. is up 5.21% from its previous closing price of $0.960.

During the last market session, Filana Therapeutics, Inc.’s stock traded between $0.945 and $1.020. Currently, there are approximately 48.31 million shares outstanding for Filana Therapeutics, Inc..

Filana Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Filana Therapeutics, Inc. Stock Price History

Filana Therapeutics, Inc.’s (FLNA) price is currently down 15.13% so far this month.

During the month of July, Filana Therapeutics, Inc.’s stock price has reached a high of $1.370 and a low of $0.856.

Over the last year, Filana Therapeutics, Inc. has hit prices as high as $4.980 and as low as $0.856.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Filana Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were analysts who downgraded Filana Therapeutics, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Filana Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Filana Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Filana Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Filana Therapeutics, Inc. (FLNA) by visiting AAII Stock Evaluator.

Relative Price Strength of Filana Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Filana Therapeutics, Inc. has a weighted four-quarter relative price strength of -18.10%, which translates to a Momentum Score of 14 and is considered to be Very Weak.

Want to learn more about how Filana Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Filana Therapeutics, Inc. Stock Price: Bottom Line

As of July 31, 2026, Filana Therapeutics, Inc.’s stock price is $1.010, which is up 5.21% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Filana Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.